Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer

Summary Background Adjuvant therapy for early breast cancer is effective but may be toxic. Our aim was to investigate the impact of the presence, timing, and duration of adjuvant chemotherapy on patients' perceptions of their quality of life (QL). Methods International Breast Cancer Study Group...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 1996-05, Vol.347 (9011), p.1279-1284
Hauptverfasser: International Breast Cancer Study Group, Hürny, C., Bernhard, J., Castiglione-Gertsch, M., Coates, A.S., Peterson, H.F., Gelber, R.D., Forbes, J.F., Rudenstam, C-M., Simoncini, E., Crivellari, D., Goldhirsch, A., Senn, H-J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background Adjuvant therapy for early breast cancer is effective but may be toxic. Our aim was to investigate the impact of the presence, timing, and duration of adjuvant chemotherapy on patients' perceptions of their quality of life (QL). Methods International Breast Cancer Study Group trial VI assessed adjuvant chemotherapy in 1475 premenopausal and perimenopausal patients, and trial VII assessed adjuvant tamoxifen or chemoendocrine therapy in 1212 postmenopausal patients with node-positive breast cancer. Patients were asked to complete a QL questionnaire_ single-item linear analogue self-assessment scales measured physical wellbeing, mood, appetite, and perceived adjustment/coping. QL was assessed in this way at the beginning of treatment, 2 months after the start of treatment, every 3 months, and at 1 and 6 months after recurrence. Findings Baseline QL scores decreased as the number of involved axillary nodes increased (for example, mean mood score: 66·1 for women with one positive node, 66·4 for two to four positive nodes, 61·3 for five to nine positive nodes, and 59·1 for ten or more positive nodes; p=0·008 for trends), and were lower in patients with oestrogen-receptor-negative than in patients with oestrogen-receptor-positive tumours (61·4 vs 66·3, pO·0009). All treatment groups showed substantial improvement in QL scores during adjuvant therapy. Patterns of QL scores reflected presence, duration, and timing of cytotoxic treatment. Longer initial cytotoxic therapy delayed improvement in QL scores. Later cytotoxic therapy had transient adverse effects. Anticipation of future therapy also affected QL scores. Interpretation Overall, chemotherapy had a measurable adverse effect on QL, but this effect was transient and minor compared with patients' adaptation/coping after diagnosis and surgery. This finding should encourage patients and doctors to choose appropriate adjuvant therapy with less concern for initial toxicity.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(96)90936-8